Harmony Biosciences Holdings Cash Flow Quality Index
Harmony Biosciences Holdings cash flow quality index. Harmony Biosciences Holdings (HRMY) has a Cash Flow Quality Index of 1.23x as of June 2026. Operating cash flow of $92.43 Million exceeds net income of $75.43 Million, indicating high earnings quality where cash backs reported profits. See financial agility of Harmony Biosciences Holdings to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Harmony Biosciences Holdings (2021–2025)
Cash flow quality index of Harmony Biosciences Holdings from 2021 to 2025. Historical Cash Flow Quality Index for Harmony Biosciences Holdings across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Harmony Biosciences Holdings (HRMY) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Harmony Biosciences Holdings Cash Flow Quality Index by Year (2021–2025)
Harmony Biosciences Holdings cash flow quality index by year from 2021 to 2025. Year-by-year earnings quality comparison for Harmony Biosciences Holdings. For the full cash flow conversion analysis, see Harmony Biosciences Holdings operating cash flow efficiency.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.19x | $348.20 Million | $158.69 Million | ▲ +45.2% |
| 2024 | 1.51x | $219.82 Million | $145.49 Million | ▼ -11.3% |
| 2023 | 1.70x | $219.39 Million | $128.85 Million | ▲ +113.9% |
| 2022 | 0.80x | $144.47 Million | $181.47 Million | ▼ -72.1% |
| 2021 | 2.85x | $98.56 Million | $34.60 Million | — |